| Display this index in Date order |
| Title & Synopsis | Date |
Price |
Order Form
|
| Abbott: Pipeline • Products • Performance • Potential Abbott researches, develops, manufactures and sells a broad and diversified line of healthcare products and services, comprising mainly prescription pharmaceuticals, nutritionals, hospital pharmaceuticals and diagnostics, in more than 130 countries. This new strategic analysis report provides a complete and critical review of the company and includes unique and independent assessments and forecasts of key products. More>> |
Aug-2009 |
£595/
$1040/
€745 |
|
| Actavis - Generic Company Intelligence Report Actavis has been one of the most acquisitive in the generic field in recent years, buying a large number of manufacturers and distributors. This report provides an insight into the company, reviewing its current business structure and activities. More>> |
Apr-2010 |
£195/
$340/
€245 |
|
| Alcon: Pipeline • Products • Performance • Potential Alcon is a research and development-driven global company which develops, manufactures and markets pharmaceuticals, surgical equipment and devices, and consumer products to treat diseases and disorders of the eye. This new strategic analysis report provides a complete and critical review of the company and includes unique and independent assessments and forecasts of key products. More>> |
Feb-2010 |
£595/
$1040/
€745 |
|
| Allergan: Pipeline • Products • Performance • Potential Allergan is a global specialty pharmaceutical company that develops and commercializes products for neurosciences, ophthalmology, medical dermatology, medical aesthetics, obesity intervention, urologics and other specialty markets. This new strategic analysis report provides a complete and critical review of the company and includes unique and independent assessments and forecasts of key products. More>> |
Apr-2009 |
£595/
$1040/
€745 |
|
| Amgen: Pipeline • Products • Performance • Potential Amgen is the world's largest biotechnology company in terms of pharmaceutical sales and R&D expenditure. This new strategic analysis report provides a complete and critical review of the company and includes unique and independent assessments and forecasts of key products. More>> |
Feb-2009 |
£595/
$1040/
€745 |
|
| Apotex - Generic Company Intelligence Report Apotex is Canada’s largest domestic pharmaceutical manufacturer. This report provides an insight into the company, reviewing its current business structure and activities. More>> |
Apr-2010 |
£195/
$340/
€245 |
|
| Aspen Pharmacare - Generic Company Intelligence Report Aspen Pharmacare is Africa's largest manufacturer of generic drugs, and the leading supplier of generic products to both the private and public sectors in South Africa. This report provides an insight into the company, reviewing its current business structure and activities. More>> |
Apr-2010 |
£195/
$340/
€245 |
|
| Astellas Pharma: Pipeline • Products • Performance • Potential Astellas Pharma aims to secure a top share in the Japanese pharmaceutical market. This new strategic analysis report provides a complete and critical review of the company and includes unique and independent assessments and forecasts of key products. More>> |
Jan-2010 |
£595/
$1040/
€745 |
|
| AstraZeneca: Pipeline • Products • Performance • Potential Following the merger of Astra and Zeneca, AstraZeneca has worked to transform itself into one of the world’s leading research-based pharmaceutical companies. This new strategic analysis report provides a complete and critical review of the company and includes unique and independent assessments and forecasts of key products. More>> |
Oct-2009 |
£595/
$1040/
€745 |
|
| Aurobindo - Generic Company Intelligence Report India-based Aurobindo was founded in 1986, and became a public company in 1995. The firm has a multi product portfolio, and has manufacturing facilities in India, China, the US and Brazil.. This report provides an insight into the company, reviewing its current business structure and activities. More>> |
Apr-2010 |
£195/
$340/
€245 |
|
| Barr Pharmaceuticals - Generic Company Intelligence Report Barr Pharmaceuticals is one of the USA’s leading generic manufacturers. This report provides an insight into the company, reviewing its current business structure and activities. More>> |
Oct-2009 |
£195/
$340/
€245 |
|
| Bayer: Pipeline • Products • Performance • Potential Bayer is a global enterprise, headquartered in Germany, with core competencies in the fields of healthcare, nutrition and high-tech materials. This new strategic analysis report provides a complete and critical review of the company and includes unique and independent assessments and forecasts of key products. More>> |
Oct-2009 |
£595/
$1040/
€745 |
|
| Biogen Idec: Pipeline • Products • Performance • Potential Biogen Idec is a global research-based company focused on the development, manufacture and commercialisation of novel therapeutics for human health care. This new strategic analysis report provides a complete and critical review of the company and includes unique and independent assessments and forecasts of key products. More>> |
Dec-2009 |
£595/
$1040/
€745 |
|
| Boehringer Ingelheim: Pipeline • Products • Performance • Potential Boehringer Ingelheim GmbH (BI) is the world's largest private pharmaceutical enterprise. The company’s activities are concentrated on two businesses: Human Pharmaceuticals and Animal Health. This new strategic analysis report provides a complete and critical review of the company and includes unique and independent assessments and forecasts of key products. More>> |
Sep-2009 |
£595/
$1040/
€745 |
|
| Bristol-Myers Squibb: Pipeline • Products • Performance • Potential Within Pharmaceuticals, BMS’ key areas of interest are cardiovascular and metabolic disorders, virology, oncology, neuroscience and immunology. This new strategic analysis report provides a complete and critical review of the company and includes unique and independent assessments and forecasts of key products. More>> |
Feb-2009 |
£595/
$1040/
€745 |
|
| Chugai: Pipeline • Products • Performance • Potential As a member of the Roche Group, Chugai has rights to develop and market all pharmaceutical products which the Roche Group decides to commercialise in Japan. This new strategic analysis report provides a complete and critical review of the company and includes unique and independent assessments and forecasts of key products. More>> |
Oct-2009 |
£595/
$1040/
€745 |
|
| Cipla - Generic Company Intelligence Report Cipla was founded in Bombay in 1935 and manufactures APIs and formulation drugs. Its products are sold in over 150 countries. This report provides an insight into the company, reviewing its current business structure and activities. More>> |
Apr-2010 |
£195/
$340/
€245 |
|
| Daiichi Sankyo: Pipeline • Products • Performance • Potential Daiichi Sankyo seems well placed to maintain its position as one of Japan’s leading pharmaceutical companies. This new strategic analysis report provides a complete and critical review of the company and includes unique and independent assessments and forecasts of key products. More>> |
Oct-2009 |
£595/
$1040/
€745 |
|
| Dainippon Sumitomo: Pipeline • Products • Performance • Potential Dainippon Sumitomo Pharma (DSP) is a research-based pharmaceutical company, headquartered in Osaka, which has resulted from the merger of Dainippon Pharmaceutical (which acts as the surviving company) and Sumitomo Pharmaceutical (a division of Sumitomo Chemical). This new strategic analysis report provides a complete and critical review of the company and includes unique and independent assessments and forecasts of key products. More>> |
Jan-2010 |
£595/
$1040/
€745 |
|
| Dr Reddy's Laboratories - Generic Company Intelligence Report Dr Reddy’s is the second largest pharmaceutical manufacturer in India, behind Ranbaxy. This report provides an insight into the company, reviewing its current business structure and activities. More>> |
Apr-2010 |
£195/
$340/
€245 |
|
| Egis - Generic Company Intelligence Report Egis was established in 1913 in Budapest, Hungary. The company has 21 subsidiaries under its direct control. This report provides an insight into the company, reviewing its current business structure and activities. More>> |
Apr-2010 |
£195/
$340/
€245 |
|
| Eisai: Pipeline • Products • Performance • Potential Headquartered in Japan, Eisai sells prescription products within the following therapeutic areas: neurology; gastroenterology; metabolic; anti-inflammatory; diagnostics and oncology. This new strategic analysis report provides a complete and critical review of the company and includes unique and independent assessments and forecasts of key products. More>> |
Nov-2009 |
£595/
$1040/
€745 |
|
| Eli Lilly: Pipeline • Products • Performance • Potential Eli Lilly is a global manufacturer and distributor of pharmaceutical therapies for cancer, cardiovascular diseases, central nervous system ailments, diabetic and endocrine system disorders, and infectious diseases. This new strategic analysis report provides a complete and critical review of the company and includes unique and independent assessments and forecasts of key products. More>> |
Jan-2010 |
£595/
$1040/
€745 |
|
| Forest Laboratories: Pipeline • Products • Performance • Potential Forest Laboratories and its subsidiaries develop, manufacture and market branded and generic forms of prescription and non-prescription pharmaceutical products, primarily in the US and Europe. This new strategic analysis report provides a complete and critical review of the company and includes unique and independent assessments and forecasts of key products. More>> |
Feb-2009 |
£595/
$1040/
€745 |
|
| Gedeon Richter - Generic Company Intelligence Report Gedeon Richter is Hungary's oldest and largest pharmaceutical manufacturer. It is one of the last major CEE pharmaceutical manufacturers not to be acquired by a multinational manufacturer. This report provides an insight into the company, reviewing its current business structure and activities. More>> |
Apr-2010 |
£195/
$340/
€245 |
|
| Gilead Sciences: Pipeline • Products • Performance • Potential Gilead Sciences is a biopharmaceutical company that discovers, develops and commercialises ethical drugs. This new strategic analysis report provides a complete and critical review of the company and includes unique and independent assessments and forecasts of key products. More>> |
Feb-2010 |
£595/
$1040/
€745 |
|
| GlaxoSmithKline: Pipeline • Products • Performance • Potential According to GSK, it supplied one quarter of the world's vaccines by the end of 2007 and had a further 20 in clinical development. This new strategic analysis report provides a complete and critical review of the company and includes unique and independent assessments and forecasts of key products. More>> |
Oct-2009 |
£595/
$1040/
€745 |
|
| Hospira - Generic Company Intelligence Report Hospira is a leading supplier of generic injectables in the USA, with a product range of 190 generic injectable products in more than 900 dosages and formulations. This report provides an insight into the company, reviewing its current business structure and activities. More>> |
Apr-2010 |
£195/
$340/
€245 |
|
| Impax - Generic Company Intelligence Report Impax focuses on the development and commercialisation of generic and branded pharmaceuticals. This report provides an insight into the company, reviewing its current business structure and activities. More>> |
Apr-2010 |
£195/
$340/
€245 |
|
| Johnson & Johnson: Pipeline • Products • Performance • Potential Johnson & Johnson's operating activities are conducted within three business segments: Medical Devices & Diagnostics, Pharmaceutical and Consumer. This new strategic analysis report provides a complete and critical review of the company and includes unique and independent assessments and forecasts of key products. More>> |
Aug-2009 |
£595/
$1040/
€745 |
|
| Krka - Generic Company Intelligence Report Krka was established in Slovenia in 1954, and has grown to become one of the largest generic drug manufacturers in Central and Eastern Europe. This report provides an insight into the company, reviewing its current business structure and activities. More>> |
Apr-2010 |
£195/
$340/
€245 |
|
| Kyowa Hakko: Pipeline • Products • Performance • Potential Kyowa Hakko operates in a diverse range of more than 30 business fields which are principally divided into Pharmaceuticals and Bio-Chemicals divisions. This new strategic analysis report provides a complete and critical review of the company and includes unique and independent assessments and forecasts of key products. More>> |
Aug-2009 |
£595/
$1040/
€745 |
|
| Lannett - Generic Company Intelligence Report Lannett looks to developing generic drugs with more secure markets and less competition, while pursuing long-term alliances with API suppliers. This report provides an insight into the company, reviewing its current business structure and activities. More>> |
Apr-2010 |
£195/
$340/
€245 |
|
| Lundbeck: Pipeline • Products • Performance • Potential Lundbeck aspires to become one of the world’s leading specialist suppliers of drugs to treat CNS diseases. This new strategic analysis report provides a complete and critical review of the company and includes unique and independent assessments and forecasts of key products. More>> |
Jun-2010 |
£595/
$1040/
€745 |
|
| Lupin - Generic Company Intelligence Report Lupin's products are available in nearly 70 countries, with its overseas business accounting for around 65% of total revenues. This report provides an insight into the company, reviewing its current business structure and activities. More>> |
Apr-2010 |
£195/
$340/
€245 |
|
| Merck KGaA: Pipeline • Products • Performance • Potential Merck KGaA is focused on the development and sales of pharmaceuticals, laboratory business and specialty chemicals. This new strategic analysis report provides a complete and critical review of the company and includes unique and independent assessments and forecasts of key products. More>> |
Jun-2009 |
£595/
$1040/
€745 |
|
| Merck & Co: Pipeline • Products • Performance • Potential Merck focuses on diseases such as AIDS, diabetes, obesity and Alzheimer's. This new strategic analysis report provides a complete and critical review of the company and includes unique and independent assessments and forecasts of key products. More>> |
Nov-2009 |
£595/
$1040/
€745 |
|
| Mitsubishi Tanabe Pharma: Pipeline • Products • Performance • Potential Mitsubishi Tanabe Pharma’s initial focus is on the development and marketing of products in the following therapeutic areas: Cardiovascular and Respiratory; Neurology; Immunology and Inflammation; and Gastrointestinal and Metabolism. This new strategic analysis report provides a complete and critical review of the company and includes unique and independent assessments and forecasts of key products. More>> |
Apr-2009 |
£595/
$1040/
€745 |
|
| Mylan - Generic Company Intelligence Report Founded in 1961, Mylan, until 2007 known as Mylan Laboratories, is one of the largest US generic drug manufacturers. This report provides an insight into the company, reviewing its current business structure and activities. More>> |
Apr-2010 |
£195/
$340/
€245 |
|
| Novartis: Pipeline • Products • Performance • Potential Novartis has become a leading company in the life sciences field and has operations in approximately 140 countries worldwide. This new strategic analysis report provides a complete and critical review of the company and includes unique and independent assessments and forecasts of key products. More>> |
Nov-2009 |
£595/
$1040/
€745 |
|
| Novo Nordisk: Pipeline • Products • Performance • Potential Novo Nordisk is a biotech-based healthcare company with the broadest diabetes product portfolio in the industry and a world leader in diabetes care. In addition, it has a leading position in haemostasis management, growth hormone therapy and hormone replacement therapy. This new strategic analysis report provides a complete and critical review of the company and includes unique and independent assessments and forecasts of key products. More>> |
May-2009 |
£595/
$1040/
€745 |
|
| Nycomed: Pipeline • Products • Performance • Potential Nycomed is active within a range of therapeutic areas, including gastroenterology, inflammation and pain, neurology, tissue management, respiratory and cardiology. This new strategic analysis report provides a complete and critical review of the company and includes unique and independent assessments and forecasts of key products. More>> |
Apr-2009 |
£595/
$1040/
€745 |
|
| Ono Pharmaceutical: Pipeline • Products • Performance • Potential Ono is involved in the development of novel medicines; the company is currently focused on the development of new treatments for diseases of the cardiovascular, respiratory and central nervous systems, as well as inflammatory and metabolic disorders. This new strategic analysis report provides a complete and critical review of the company and includes unique and independent assessments and forecasts of key products. More>> |
Feb-2010 |
£595/
$1040/
€745 |
|
| Otsuka: Pipeline • Products • Performance • Potential Otsuka Pharmaceutical Company (OPC) is one of the largest healthcare companies in Japan and one of the largest privately-held firms in the world. This new strategic analysis report provides a complete and critical review of the company and includes unique and independent assessments and forecasts of key products. More>> |
Jan-2009 |
£595/
$1040/
€745 |
|
| Par Pharmaceutical - Generic Company Intelligence Report On 14th October 2008 Par announced resizing its generic unit but continues to develop and manufacture innovative branded pharmaceuticals for specialty markets. This report provides an insight into the company, reviewing its current business structure and activities. More>> |
Apr-2010 |
£195/
$340/
€245 |
|
| Partnering in the Global Generics Industry 2009: A guide to companies Facts, statistics and insights on 170 medium-sized generic manufacturers from 40 countries. More>> |
Oct-2009 |
£595/
$1040/
€745 |
|
| Perrigo - Generic Company Intelligence Report Founded in 1887, Perrigo is the largest manufacturer of store brand OTCs and nutritional products in the United States. This report provides an insight into the company, reviewing its current business structure and activities. More>> |
Apr-2010 |
£195/
$340/
€245 |
|
| Pfizer: Pipeline • Products • Performance • Potential Pfizer is the world's largest ethical pharmaceutical company. The company has a broad portfolio, with strengths in the areas of cardiovascular disease, central nervous system disorders, inflammatory disease, metabolic disorders, infectious diseases and oncology. This new strategic analysis report provides a complete and critical review of the company and includes unique and independent assessments and forecasts of key products. More>> |
Jul-2009 |
£595/
$1040/
€745 |
|
| Pharmaceutical Companies Performance: Winners and losers in a recession hit industry Using full year 2008 results and providing 5-year views, this report provides over 150 ranking tables for 100 companies. More>> |
Jan-2010 |
£495/
$865/
€620 |
|
| Pliva - Generic Company Intelligence Report Pliva is based in Croatia, and is one of that country’s leading manufacturing companies. It is also one of the largest pharmaceutical manufacturers in central Europe. This report provides an insight into the company, reviewing its current business structure and activities. More>> |
Oct-2009 |
£195/
$340/
€245 |
|
| Ranbaxy - Generic Company Intelligence Report Acquired by Daiichi Sankyo in October 2008, Ranbaxy is India's leading pharmaceutical company and is at the forefront of attempts to bring cheaper generic HIV/AIDS medicines to developing countries. This report provides an insight into the company, reviewing its current business structure and activities. More>> |
Apr-2010 |
£195/
$340/
€245 |
|
| ratiopharm - Generic Company Intelligence Report ratiopharm, founded in 1974, claims to be the leading generic company in Germany, and the third largest pharmaceutical company overall, in terms of prescriptions. In January 2009, ratiopharm’s founder died. The VEM Group, which owns ratiopharm, confirmed in early 2009 that the company would be put up for sale. This report provides an insight into the company, reviewing its current business structure and activities. More>> |
Apr-2010 |
£195/
$340/
€245 |
|
| Recordati: Pipeline • Products • Performance • Potential Recordati is active in the following areas of research: Cardiovascular; Central Nervous System, Gastroenterology/Urology and Anti-infectives. However, future research efforts will focus on fixed combinations in the treatment of hypertension and the development of therapies for micturition disorders. This new strategic analysis report provides a complete and critical review of the company and includes unique and independent assessments and forecasts of key products. More>> |
Sep-2009 |
£595/
$1040/
€745 |
|
| Roche: Pipeline • Products • Performance • Potential According to Roche, it has become a market leader in oncology, transplantation and virology, and the world leader in in vitro diagnostics. This new strategic analysis report provides a complete and critical review of the company and includes unique and independent assessments and forecasts of key products. More>> |
Jun-2009 |
£595/
$1040/
€745 |
|
| Sandoz - Generic Company Intelligence Report Sandoz is currently the second largest generic manufacturer in the world, behind Teva Pharmaceutical Industries. This report provides an insight into the company, reviewing its current business structure and activities. More>> |
Apr-2010 |
£195/
$340/
€245 |
|
| sanofi-aventis - Generic Company Intelligence Report sanofi-aventis' forays into generics came initially through its Winthrop subsidiary, but have expanded in recent years, most notably with the acquisition of the Czech Republic-based Zentiva. This report provides an insight into the company, reviewing its current business structure and activities. More>> |
Apr-2010 |
£195/
$340/
€245 |
|
| sanofi-aventis: Pipeline • Products • Performance • Potential sanofi-aventis is now the fourth largest pharmaceutical group in the world and first in Europe. Its aim is to do more, perform better and move faster in the field of health. This new strategic analysis report provides a complete and critical review of the company and includes unique and independent assessments and forecasts of key products. More>> |
Sep-2009 |
£595/
$1040/
€745 |
|
| Sawai Pharmaceuticals - Generic Company Intelligence Report Sawai Pharmaceuticals is at the forefront of the Japanese generic market. It deals in the export and import, manufacturing and sales of pharmaceutical products and healthcare foods. This report provides an insight into the company, reviewing its current business structure and activities. More>> |
Apr-2010 |
£195/
$340/
€245 |
|
| Schering-Plough: Pipeline • Products • Performance • Potential Schering-Plough, based in New Jersey in the US, is a global research-based healthcare company with leading prescription, consumer and animal health products. This new strategic analysis report provides a complete and critical review of the company and includes unique and independent assessments and forecasts of key products. More>> |
Jan-2009 |
£595/
$1040/
€745 |
|
| Shionogi: Pipeline • Products • Performance • Potential Shionogi is active in the following therapeutic areas: Infectious Diseases, Metabolic Syndrome, Anticancer, Neurology, Allergy and Circulatory. This new strategic analysis report provides a complete and critical review of the company and includes unique and independent assessments and forecasts of key products. More>> |
Mar-2010 |
£595/
$1040/
€745 |
|
| Shire: Pipeline • Products • Performance • Potential Shire is a leading specialty pharmaceutical company traditionally focused on the treatment of attention deficit hyperactivity disorder (ADHD) and gastrointestinal disorders. This new strategic analysis report provides a complete and critical review of the company and includes unique and independent assessments and forecasts of key products. More>> |
Aug-2009 |
£595/
$1040/
€745 |
|
| Simcere Pharmaceuticals - Generic Company Intelligence Report Simcere Pharmaceutical serves the Chinese pharmaceutical market. It deals in the export and import, manufacturing and sales of pharmaceutical products and healthcare foods. This report provides an insight into the company, reviewing its current business structure and activities. More>> |
Apr-2010 |
£195/
$340/
€245 |
|
| Solvay: Pipeline • Products • Performance • Potential Operating in the three sectors of Pharmaceuticals, Chemicals and Plastics, Solvay is represented worldwide. This new strategic analysis report provides a complete and critical review of the company and includes unique and independent assessments and forecasts of key products. More>> |
Sep-2009 |
£595/
$1040/
€745 |
|
| Stada Arzneimittel - Generic Company Intelligence Report Stada Arzneimittel is one of the two major independent German generic manufacturers, along with ratiopharm. This report provides an insight into the company, reviewing its current business structure and activities. More>> |
Apr-2010 |
£195/
$340/
€245 |
|
| Sun Pharmaceutical - Generic Company Intelligence Report India-based Sun Pharmaceutical Industries was established in 1983, initially selling psychiatry-related products in West Bengal and Bihar. This report provides an insight into the company, reviewing its current business structure and activities. More>> |
Apr-2010 |
£195/
$340/
€245 |
|
| Takeda: Pipeline • Products • Performance • Potential Takeda specialises in the areas of metabolic, cardiovascular, gastrointestinal, anticancer, musculoskeletal and CNS products. This new strategic analysis report provides a complete and critical review of the company and includes unique and independent assessments and forecasts of key products. More>> |
Nov-2009 |
£595/
$1040/
€745 |
|
| Teva Pharmaceutical Industries - Generic Company Intelligence Report Teva is the largest generic pharmaceutical manufacturer in the world. This report provides an insight into the company, reviewing its current business structure and activities. More>> |
Apr-2010 |
£195/
$340/
€245 |
|
| The True State of the Pharmaceutical Industry A thought-provoking report that strips away M&A activity and the effects of currency exchange to reveal the true performance trends of 141 leading companies. More>> |
Dec-2008 |
£495/
$865/
€620 |
|
| UCB: Pipeline • Products • Performance • Potential UCB is a global biopharmaceutical company dedicated to the research, development and commercialisation of innovative pharmaceutical and biotechnology products in the fields of CNS disorders, allergy/respiratory diseases, immune and inflammatory disorders, plus oncology. This new strategic analysis report provides a complete and critical review of the company and includes unique and independent assessments and forecasts of key products. More>> |
Dec-2009 |
£595/
$1040/
€745 |
|
| Watson Pharmaceuticals - Generic Company Intelligence Report Watson Pharmaceuticals was founded in 1984 in Corona, California. The company has facilities across the USA, and in the UK and China. It vies with Barr and Mylan as the USA’s largest generic manufacturer. This report provides an insight into the company, reviewing its current business structure and activities. More>> |
Apr-2010 |
£195/
$340/
€245 |
|
| Who's Developing What in Drug Delivery? This report will enable you to understand the structure, performance, R&D and products of 130 leading drug delivery companies. More>> |
Nov-2009 |
£595/
$1040/
€745 |
|
| Who's Developing What in Global Biopharmaceuticals? A critical assessment of 50 leading companies, their research, products, partners and performance. More>> |
Sep-2008 |
£695/
$1215/
€870 |
|
| Who's Developing What in New Cancer Drugs 2007? The new 6th edition of this respected management report is the essential reference work for everyone in the field. The report covers 121 companies - from the largest blue-chip multinational to smaller specialist organisations - and all phases of development from research to launched products. More>> |
Nov-2007 |
£495/
$865/
€620 |
|
| Wockhardt - Generic Company Intelligence Report The Indian company, Wockhardt Limited, was founded nearly four decades ago, and today claims its place amongst the country's top research and technology oriented pharmaceutical companies. This report provides an insight into the company, reviewing its current business structure and activities. More>> |
Apr-2010 |
£195/
$340/
€245 |
|
| Wyeth: Pipeline • Products • Performance • Potential Wyeth is one of the world’s largest research-based pharmaceutical and healthcare products companies and is a leader in the discovery, development, manufacturing and marketing of pharmaceuticals, biotechnology products, vaccines, non-prescription medicines and animal health products. This new strategic analysis report provides a complete and critical review of the company and includes unique and independent assessments and forecasts of key products. More>> |
Mar-2009 |
£595/
$1040/
€745 |
|
| Zentiva - Generic Company Intelligence Report Zentiva specialises in the development of generics, and holds leading market positions in both the Czech and Slovak Republics. This report provides an insight into the company, reviewing its current business structure and activities. More>> |
Oct-2009 |
£195/
$340/
€245 |
|
| Zydus Cadila - Generic Company Intelligence Report Cadila was founded in 1952, and was restructured in 1992 to become the Zydus Cadila Group. The Zydus Group is aiming to become one of the top three healthcare companies in India and a global player. This report provides an insight into the company, reviewing its current business structure and activities. More>> |
Apr-2010 |
£195/
$340/
€245 |